Abstract
Thymomas are rare thymic epithelial tumors (TETs) with favorable long-term prognosis after R 0 resection surgery: 5-year overall disease-free survival is reported to range from 71% to 92% (1,2). Meanwhile, pleural relapse is a hallmark of thymoma (75% of recurrences) (3). Re-resection is a major predictor of favorable outcome in this setting and is recommend by the European Society for Medical Oncology (ESMO) and the National Comprehensive Cancer Network (NCCN). However, there is still no formal consensus on the surgical practice. Some authors advocate debulking surgery, complete re-resection, or extra pleural pneumonectomy (EPP) in selected patients associated with variable morbidity and mortality. Given indolent progression and specific localization of those recurrence, some authors advocate a new concept of radical cytoreductive surgery associated with Intra-Thoracic Chemo-Hyperthermia (ITCH) based on previous studies realized in mesothelioma.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
